MSB 4.89% $1.07 mesoblast limited

fin review - top 4 biotech's

  1. 632 Posts.
    we may not have got the well deserved re-rate yet on the back of a stellar 2013 with plenty of great news items and milestones…. but we're well and truly on the radar of plenty more investors after this article. 2014 is going to be the company maker for MSB IMO. Sooooo…. much to look forward to with results due in many indications…. Good luck… and get on board while you can!

    http://www.afr.com/p/business/companies/four_biotechnology_stocks_to_watch_YwTgFfUrbVMhk7xZzIFN5O

    Four biotechnology stocks to watch in 2014

    "Whether it’s an impending decision by a regulator or the release of much-awaited clinical data, the following four biotechnology companies have some milestones due in the coming 12 months."

    Mesoblast, prana, AHZ and SRX is one of the 4 reviewed by author Jessica Gardner

    I've got the first 3 so happy for the media coverage…..
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.07
Change
-0.055(4.89%)
Mkt cap ! $1.221B
Open High Low Value Volume
$1.14 $1.16 $1.06 $8.816M 8.055M

Buyers (Bids)

No. Vol. Price($)
1 280000 $1.07
 

Sellers (Offers)

Price($) Vol. No.
$1.07 2000 1
View Market Depth
Last trade - 16.10pm 29/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.